Stay updated on Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial page.

Latest updates to the Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial page
- Check7 days agoChange DetectedFooter now shows Revision: v3.5.2, replacing Revision: v3.5.0. This is a technical update with no impact on study information or user actions.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedAdded 'Squamous cell carcinoma of the head and neck' as a listed condition in the study details.SummaryDifference0.1%

- Check35 days agoChange DetectedRevision v3.5.0 added; revision v3.4.3 removed.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check71 days agoChange DetectedAdded Revision: v3.4.2; removed the government funding lapse notice and the older Revision: v3.4.1 entry.SummaryDifference0.4%

- Check78 days agoChange DetectedThe page now displays a government funding lapse notice and the site version was updated to Revision: v3.4.1, which are administrative updates and do not affect core study content or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial page.